TMO vs ZYME · P/E 24, rev $44.56B vs rev $76.3M
Thermo Fisher Scientific Inc (TMO) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
TMO currently screens at market cap $153.06B and trailing P/E 23.8. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the TMO and ZYME stock pages for the full models.
Not investment advice.